Cabaletta Bio Shares Are Trading Lower. The Company Announced Initial Clinical Data From Each of the First Two Patients Dosed With CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE Trials.
Cabaletta Bio Shares Are Trading Lower. The Company Announced Initial Clinical Data From Each of the First Two Patients Dosed With CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE Trials.
cabaletta bio的股份正在交投下跌。公司宣佈了第一和第二位在1/2期RESET-Myositis和RESET-SLE試驗中接受CABA-201劑量的患者的初始臨床數據。
Cabaletta Bio Shares Are Trading Lower. The Company Announced Initial Clinical Data From Each of the First Two Patients Dosed With CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE Trials.
Cabaletta bio股價下跌。該公司宣佈第一和第二名患者在第1/2期RESET-Myositis和RESET-SLE試驗中注射CABA-201的初步臨床數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。